Want to join the conversation?
As part of a partnership with $AZN & MedImmune, $CELG said it has launched the FUSION clinical development program of durvalumab (MEDI4736), a monoclonal antibody designed for the treatment of cancer. This program is to develop & commercialize durvalumab across a range of blood cancers & will include four studies.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.